Maryland Just Adopted New Cannabis Packaging and Product Rules, and They Take Effect Tomorrow
Maryland cannabis packaging rules adopted on August 13, 2026 take effect September 14, which means the comment period readers were told to watch closed six weeks ago. The package removes the plain packaging requirement while expanding the prohibition on…
CED Cannabis News Digest: Puerto Rico Inspections, Pennsylvania’s Cannabis Divide, and Phuket’s 90-Day Crackdown
This cannabis news digest highlights Puerto Rico cannabis inspections as a key development in medical cannabis oversight. It also covers Pennsylvania's marijuana and hemp policy divide and Phuket's 90-day enforcement crackdown. These stories focus on…
CED Cannabis News Digest: Enforcement and Licensing Updates
This cannabis news digest covers new york illicit cannabis enforcement efforts, d.c.'s medical cannabis licensing denial, and thailand's prescription-only cannabis flower reminder. These stories highlight key regulatory changes shaping legal cannabis…
Cannabis and Mental Health: July 2026 Regulatory Digest
This digest examines cannabis and mental health through the lens of adolescent psychiatric risk, shifting THC regulations, and market noise overshadowing clinical evidence. Dr. Caplan offers commentary on separating meaningful signals from commercial…
DEA Update on Scheduling Synthetic Cannabinoids in Schedule I
The DEA scheduling synthetic cannabinoids update highlights the placement of four novel compounds into Schedule I. These synthetic cannabinoids pose significant public health risks due to their high potency and unknown safety profiles. Clinicians should…
Cannabis News Digest: Clinical Analysis of 12 Articles June 2026
This cannabis news digest reviews 12 articles from June 14, 2026, examining cannabis industry developments, regulatory changes, and enforcement actions. Dr. Caplan provides clinical commentary on the fragmented landscape affecting patient care. The…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
Synthetic Substances Regulatory Updates 2026: Key DEA Actions
This update covers synthetic substances regulatory updates 2026 with 20 key DEA scheduling actions. These include synthetic cannabinoids, opioids, and benzodiazepine analogs. The regulatory changes highlight challenges for clinicians managing cannabis…
IIPR and Cannabis Reform: 280E Relief and Schedule III Upside – April 16, 2026
Schedule III cannabis reclassification could transform federal policy by easing research restrictions and providing 280e tax relief. This change may improve clinical access and reduce costs for medical cannabis businesses. Patients and clinicians should…
Wildings in Newport: From Grand Store to Illicit Cannabis Farm
Illicit cannabis farm safety risks are significant in Newport, Wales, where a grand department store was converted into an unregulated cannabis cultivation site. These illicit operations lack quality control and pose contamination dangers. Patients must…
